Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycerol-3-phosphate dehydrogenase (GPDH) is an enzyme that catalyzes the reversible redox conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P). This reaction is central to carbohydrate and lipid metabolism, including respiration, glycolysis, and phospholipid biosynthesis. There are two main forms: cytosolic GPDH (GPD1), an NAD+-dependent enzyme, and mitochondrial GPDH (GPD2), which uses quinol/quinone. GPDH functions as a dimer with two protein domains: an N-terminal NAD-binding domain and a C-terminal substrate-binding and catalytic domain. Key active site residues include Lys120, Asp260, Arg269, and Asn270. The enzyme undergoes conformational changes upon substrate binding, utilizing a hydride transfer mechanism where Lys120 donates a proton to the carbonyl of DHAP. GPDH is highly conserved across virtually all organisms and plays a critical role in the glycerol phosphate shuttle, connecting glycolysis to lipid metabolism and maintaining cellular redox balance. Its role in glycerol metabolism and connection to insulin signaling and obesity suggests potential relevance to metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycerol-3-phosphate dehydrogenase (GPDH).